GlassScriptPhysician profile
Steven R Schubert
NPI 1255321543
$5,623.80
in general payments reported to CMS, 2019-2025
27 companies · $1,268 in 2025
The $1,268 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $488 · 2020: $547 · 2021: $697 · 2022: $790 · 2023: $1,217 · 2024: $618 · 2025: $1,268.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,784 · Honoraria: $300 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,783.56 |
| Honoraria | $300.00 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,809.70 | 2019-2025 | Otezla, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $866.96 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Astrazeneca Pharmaceuticals LP | $640.65 | 2019-2022 | |
| Novo Nordisk INC | $351.87 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $320.85 | 2023-2025 | Jardiance, Zepbound, Mounjaro |
| Chiesi USA, INC. | $300.00 | 2025 | Juxtapid |
| Amarin Pharma, INC. | $292.80 | 2019-2021 | |
| Astellas Pharma US INC | $140.14 | 2023-2024 | Veozah |
| Novartis Pharmaceuticals Corporation | $124.92 | 2019-2025 | |
| Watermark Medical, INC. | $123.49 | 2022 | |
| Intuitive Surgical, INC. | $97.08 | 2023 | Da Vinci Surgical System |
| Regeneron Healthcare Solutions, INC. | $79.26 | 2019-2024 | Praluent, Evkeeza |
| Abbvie INC. | $78.54 | 2021-2025 | |
| Allergan, INC. | $66.58 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $53.95 | 2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amryt Pharma Holdings LTD | $41.07 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $30.20 | 2022-2023 | Eliquis |
| Neurocrine Biosciences, INC. | $29.80 | 2022 | |
| Ibsa Pharma INC. | $28.02 | 2020-2023 | Tirosint, Licart |
| Pfizer INC. | $26.80 | 2019-2025 | |
| Vbi Vaccine (Delaware) INC. | $25.73 | 2022-2023 | Prehevbrio |
| Horizon Therapeutics Plc | $18.81 | 2022 | |
| Sanofi-Aventis U.S. LLC | $18.14 | 2019 | |
| Medicure Pharma INC. | $17.54 | 2022 | |
| Jazz Pharmaceuticals INC. | $15.29 | 2022 | |
| Daiichi Sankyo INC. | $14.77 | 2021 | |
| Shire North American Group INC | $10.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Schubert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.